BACKGROUND: Microsatellite instability (MSI) constitutes an important oncogenic molecular pathway in colorectal cancer (CRC), representing approximately 15% of all colorectal malignant tumours. In roughly one third of the cases, the underlying DNA mismatch repair (MMR) defect is inherited through the transmission of a mutation in one of the genes involved in MMR, predominantly MSH2 and MLH1, or less frequently, MSH6 or PMS2. In the overwhelming number of sporadic cases, MSI results from epigenetic MLH1 silencing through hypermethylation of its promoter. MMR deficiency promotes colorectal oncogenesis through the accumulation of numerous mutations in crucial target genes harbouring mononucleotide repeats, notably in those involved in the control of cell proliferation and differentiation, as well as DNA damage signalling and repair. DESIGN: In this review, we describe the molecular aspects of the MMR system and the biological consequences of its defect on the oncogenic process, and we discuss the various experimental systems used to evaluate the efficacy of cytotoxic drugs on MSI colorectal cells lines. There is increasing evidence showing that MSI CRCs differ from all CRCs in terms of prognosis and response to the treatment. We report the clinical studies that have evaluated the prognostic and predictive value of MSI status on clinical outcome in patients treated with various chemotherapy regimens used in the adjuvant setting or for advanced CRCs. CONCLUSION: In view of this, the opportunity of a systematic MSI phenotyping in the clinical management of patients with CRC is further discussed.
BACKGROUND: Microsatellite instability (MSI) constitutes an important oncogenic molecular pathway in colorectal cancer (CRC), representing approximately 15% of all colorectal malignant tumours. In roughly one third of the cases, the underlying DNA mismatch repair (MMR) defect is inherited through the transmission of a mutation in one of the genes involved in MMR, predominantly MSH2 and MLH1, or less frequently, MSH6 or PMS2. In the overwhelming number of sporadic cases, MSI results from epigenetic MLH1 silencing through hypermethylation of its promoter. MMR deficiency promotes colorectal oncogenesis through the accumulation of numerous mutations in crucial target genes harbouring mononucleotide repeats, notably in those involved in the control of cell proliferation and differentiation, as well as DNA damage signalling and repair. DESIGN: In this review, we describe the molecular aspects of the MMR system and the biological consequences of its defect on the oncogenic process, and we discuss the various experimental systems used to evaluate the efficacy of cytotoxic drugs on MSI colorectal cells lines. There is increasing evidence showing that MSI CRCs differ from all CRCs in terms of prognosis and response to the treatment. We report the clinical studies that have evaluated the prognostic and predictive value of MSI status on clinical outcome in patients treated with various chemotherapy regimens used in the adjuvant setting or for advanced CRCs. CONCLUSION: In view of this, the opportunity of a systematic MSI phenotyping in the clinical management of patients with CRC is further discussed.
Authors: C Miquel; S Jacob; S Grandjouan; A Aimé; J Viguier; J-C Sabourin; A Sarasin; A Duval; F Praz Journal: Oncogene Date: 2007-03-26 Impact factor: 9.867
Authors: Kriste A Lewis; Jamie Bakkum-Gamez; Ralitsa Loewen; Amy J French; Stephen N Thibodeau; William A Cliby Journal: Genes Chromosomes Cancer Date: 2007-12 Impact factor: 5.006
Authors: Hai-Ri Li; Elena I Shagisultanova; Kentaro Yamashita; Zhe Piao; Manuel Perucho; Sergei R Malkhosyan Journal: Cancer Res Date: 2004-07-15 Impact factor: 12.701
Authors: Petr Cejka; Lovorka Stojic; Nina Mojas; Anna Marie Russell; Karl Heinimann; Elda Cannavó; Massimiliano di Pietro; Giancarlo Marra; Josef Jiricny Journal: EMBO J Date: 2003-05-01 Impact factor: 11.598
Authors: Rene Rodriguez; Lasse Tengbjerg Hansen; Geraldine Phear; Jennifer Scorah; Mogens Spang-Thomsen; Angela Cox; Thomas Helleday; Mark Meuth Journal: Clin Cancer Res Date: 2008-09-01 Impact factor: 12.531
Authors: Mark A Jenkins; Shinichi Hayashi; Anne-Marie O'Shea; Lawrence J Burgart; Tom C Smyrk; David Shimizu; Paul M Waring; Andrew R Ruszkiewicz; Aaron F Pollett; Mark Redston; Melissa A Barker; John A Baron; Graham R Casey; James G Dowty; Graham G Giles; Paul Limburg; Polly Newcomb; Joanne P Young; Michael D Walsh; Stephen N Thibodeau; Noralane M Lindor; Loïc Lemarchand; Steven Gallinger; Robert W Haile; John D Potter; John L Hopper; Jeremy R Jass Journal: Gastroenterology Date: 2007-04-25 Impact factor: 22.682
Authors: A Buckowitz; H-P Knaebel; A Benner; H Bläker; J Gebert; P Kienle; M von Knebel Doeberitz; M Kloor Journal: Br J Cancer Date: 2005-05-09 Impact factor: 7.640
Authors: N Puebla-Osorio; J Kim; S Ojeda; H Zhang; O Tavana; S Li; Y Wang; Q Ma; K S Schluns; C Zhu Journal: Oncogene Date: 2013-06-10 Impact factor: 9.867
Authors: Bryony A Thompson; David E Goldgar; Carol Paterson; Mark Clendenning; Rhiannon Walters; Sven Arnold; Michael T Parsons; Walsh Michael D; Steven Gallinger; Robert W Haile; John L Hopper; Mark A Jenkins; Loic Lemarchand; Noralane M Lindor; Polly A Newcomb; Stephen N Thibodeau; Joanne P Young; Daniel D Buchanan; Sean V Tavtigian; Amanda B Spurdle Journal: Hum Mutat Date: 2012-10-11 Impact factor: 4.878
Authors: E J Th Belt; E A te Velde; O Krijgsman; R P M Brosens; M Tijssen; H F van Essen; H B A C Stockmann; H Bril; B Carvalho; B Ylstra; H J Bonjer; G A Meijer Journal: Ann Surg Oncol Date: 2011-10-12 Impact factor: 5.344